Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
san francisco blog main
3
×
san francisco top stories
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abeona therapeutics
accent therapeutics
achilles therapeutics
akouos
alder biopharmaceuticals
alexion pharmaceuticals
alnylam pharmaceuticals
alopecia areata
amarin
amgen
What
drug
3
×
market
3
×
fda
medicine
patients
sets
advantages
ago
approved
bar
battle
bio
brings
cancer
cannabis
data
derivative
eisai
epilepsy
expect
flags
form
gamble
gw
gw’s
higher
incidence
lorcaserin
loss
marijuana
marketing
medco’s
mover
new
payers
pharmaceuticals
physicians
plan
post
pricing
Language
unset
Current search:
market
×
drug
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug